Brief TOC
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6. Global Macrolide Antibiotics Market, by Drug
6.1 Introduction
6.2 Azithromycin
6.3 Clarithromycin
6.4 Erythromycin
6.5 Fidaxomicin
6.6 Telithromycin
7. Global Macrolide Antibiotics Market, by Route of Administration
7.1 Introduction
7.2 Infection Due to Mycoplasma Pneumonia, Legionella Sp, or Bordetella pertussis
7.3 Symptomatic Cat-scratch Disease
7.4 Bacillary Angiomatosis
7.5 Peliosis Hepatis in Patients with AIDS
7.6 Cerebral Toxoplasmosis
7.7 Uncomplicated Skin Infections
7.8 Others
7.8.1 Babesiosis
7.8.2 Chlamydia Trachomatis Urethritis and Cervicitis
8. Global Macrolide Antibiotics Market, by End User
8.1 Introduction
8.2 Hospitals
8.3 Dermatology Clinics
8.4 Pharmaceutical Companies
8.5 Others
9. Global Macrolide Antibiotics Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Australia
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Company Landscape
10.1 Introduction
10.2 Market share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1 Merck Sharp & Dohme Corp
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Pfizer Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Teva Pharmaceutical Industries Ltd.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Fresenius Kabi USA
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Sandoz International GmbH
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Macrolide Pharmaceuticals
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Neo QuÃmica
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Healthcare Industry
13 Appendix
